Ingrid Hopper
Hopper, Ingrid
VIAF ID: 185146331968218692387 (Personal)
Permalink: http://viaf.org/viaf/185146331968218692387
Preferred Forms
- 100 1 _ ‡a Hopper, Ingrid
- 100 0 _ ‡a Ingrid Hopper
4xx's: Alternate Name Forms (2)
Works
Title | Sources |
---|---|
Attitudes of Patients and Prescribing Clinicians to Polypharmacy and Medication Withdrawal in Heart Failure. | |
Cardiac effects of non-cardiac drugs | |
Celiac Disease and Drug Absorption: Implications for Cardiovascular Therapeutics | |
Clinical quality registries for clinician-level reporting: strengths and limitations. | |
Comorbidities in Heart Failure: Are There Gender Differences? | |
Complementary medicine use by community-dwelling older Australians | |
Complementary therapies and the medical profession: a study of medical students' attitudes. | |
Cosmetic tourism for breast augmentation: a systematic review. | |
Dementia, cognitive impairment and proton pump inhibitor therapy: A systematic review | |
Digoxin Withdrawal Worsens Clinical Status in Stable Patients With Heart Failure Receiving Optimal Contemporaneous Therapy—A Randomized Controlled Trial | |
Does Statin Benefits Patients with Heart Failure Undergoing Percutaneous Coronary Intervention? Findings from the Melbourne Interventional Group Registry. | |
Establishing the acceptability of a brief patient reported outcome measure and feasibility of implementing it in a breast device registry - a qualitative study | |
Evaluating recruitment strategies for AUSPICE, a large Australian community-based randomised controlled trial | |
Heart failure and dipeptidyl peptidase-4 inhibitors | |
High risk device registries: Global value, costs, and sustainable funding | |
Impact of a model of care for heart failure in-patients to reduce variation in care - a quality improvement project | |
Impact of heart failure and changes to volume status on liver stiffness: non-invasive assessment using transient elastography. | |
Improving the safety of breast implants: implant-associated lymphoma. | |
In memoriam Henry Krum, 1958-2015. | |
National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Guidelines for the Prevention, Detection, and Management of Heart Failure in Australia 2018 | |
Neprilysin inhibitors preserve renal function in heart failure | |
The Ongoing Evolution of Optimal Clinical Endpoints for Heart Failure Trials | |
Pilot for the Australian Breast Device Registry (ABDR): a national opt-out clinical quality registry for breast device surgery | |
Polypharmacy in the heart failure patient : are all prescribed drug classes required?, 2015: | |
Potential mechanisms underlying the cardiovascular benefits of sodium glucose cotransporter 2 inhibitors: a systematic review of data from preclinical studies | |
Prevention of diabetes and reduction in major cardiovascular events in studies of subjects with prediabetes: meta-analysis of randomised controlled clinical trials | |
Probable fenofibrate-induced acute generalized exanthematous pustulosis. | |
Qualified privilege legislation to support clinician quality assurance: balancing professional and public interests | |
Rationale and design of a randomized controlled trial of pneumococcal polysaccharide vaccine for prevention of cardiovascular events: The Australian Study for the Prevention through Immunization of Cardiovascular Events (AUSPICE). | |
Statins in CHF | |
Sympathetic Response and Outcomes Following Renal Denervation in Patients With Chronic Heart Failure: 12-Month Outcomes From the Symplicity HF Feasibility Study. | |
Systematic review with meta-analysis: risk of adverse cardiovascular events with proton pump inhibitors independent of clopidogrel | |
United we stand, divided we conquer: Pilot study of multidisciplinary General Medicine Heart Failure Care Program. | |
Updated meta-analysis on antithrombotic therapy in patients with heart failure and sinus rhythm | |
The Utility of Predicting Hospitalizations Among Patients With Heart Failure Using mHealth: Observational Study | |
Withdrawal of antihypertensive drugs in older people | |
Worsening renal function during renin-angiotensin-aldosterone system inhibitor initiation and long-term outcomes in patients with left ventricular systolic dysfunction |